Supporting Information
) A correlation plot of k off against: A) Number of non-hydrogen atom; B) Experimental LogP; C) K i with the human sEH; D) A correlation plot of k off against K i (Zoomed in region highlighted in Figure S1C ) ...... 3 Figure S2 ) Binding pocket of human sEH with inhibitor 18 (TPPU) bound. The green region indicates hydrophobic residues, including Ala, Leu, Phe, Met, Cys and Ile. More intense green color indicates more hydrophobic regions. The graphics were prepared by The PyMOL Molecular Graphics System, Version 1. Figure S1 ) A correlation plot of k off against: A) Number of non-hydrogen atom; B) Experimental LogP; C) K i with the human sEH; D) A correlation plot of k off against K i (Zoomed in region highlighted in Figure S1C A variety of high throughput assays can be used to select the more potent sEH inhibitors as was done with the NIH drug-like library (NIH Roadmap project). 1 The FRET based assay previously allows a rapid way to distinguish among the very best sEH inhibitors. As shown in Fig. S1C , there is a good correlation between K i and k off . However, Fig S1D demonstrates for fine optimization of inhibitor potency and enzyme occupancy both K i and k off should be determined. Mice (n=4) were treated by oral dosing with a cassette of 3 compounds (0.3 mg/kg of each compounds dissolved in 20% PEG400 in oleic acid rich triglycerides). The graphics and statistics were prepared by SigmaPlot (SysTat Software, San Jose, CA). The pharmacokinetic profiles of the inhibitors were calculated by Winonlin ® based on the best fit model of one compartmental analysis.
inhibitor 18/ TPPU Figure S6 ) Pharmacokinetic profile of sEH inhibitors (Cassette 2) in mice.
Mice (n=4) were treated by oral dosing with a cassette of 3 compounds (0.3 mg/kg of each compounds dissolved in 20% PEG400 in oleic acid rich triglycerides). The graphics and statistics were prepared by SigmaPlot (SysTat Software, San Jose, CA). The pharmacokinetic profiles of the inhibitors were calculated by Winonlin ® based on the best fit model of one compartmental analysis.
Figure S7) Pharmacokinetic profile of sEH inhibitors (Cassette 3) in mice.
Inhibitor 30 Figure S8 ) Pharmacokinetic profile of sEH inhibitors (Cassette 4) in mice.
Mice (n=4) were treated by oral dosing with a cassette of 3 compounds (0.3 mg/kg of each compounds dissolved in 20% PEG400 in oleic acid rich triglycerides). The graphics and statistics were prepared by SigmaPlot (SysTat Software, San Jose, CA). The pharmacokinetic profiles of the inhibitors were calculated by Winonlin ® based on the best fit model of one compartmental analysis. Mice (n=4) were treated by oral dosing with a cassette of 4 compounds (0.3 mg/kg of each compounds dissolved in 20% PEG400 in oleic acid rich triglycerides). The pharmacokinetic profiles of the inhibitors were calculated by Winonlin ® based on the best fit model of one compartmental analysis.
Figure S10) Pharmacokinetic profile of sEH inhibitors (Cassette 6) in mice.
Mice (n=4) were treated by oral dosing with a cassette of 5 compounds (0.3 mg/kg of each compounds dissolved in 20% PEG400 in oleic acid rich triglycerides). The graphics and statistics were prepared by SigmaPlot (SysTat Software, San Jose, CA). The pharmacokinetic profiles of the inhibitors were calculated by Winonlin ® based on the best fit model of one compartmental analysis.
Figure S11) Pharmacokinetic profile of sEH inhibitors in rat.
Rat (n=4) were treated by oral dosing with a cassette of 4 compounds (0.3 mg/kg of each compounds dissolved in 20% PEG400 in oleic acid rich triglycerides). The graphics and statistics were prepared by SigmaPlot (SysTat Software, San Jose, CA). The pharmacokinetic profiles of the inhibitors were calculated by Winonlin ® based on the best fit model of one compartmental analysis.
Figure S12) New Inhibitors Improve Exposure after Oral Administration at 0.3 mg/kg over potency 
TPAU

Experimental Section Chemistry
General Synthetic Scheme: General All reagents and solvent were purchased from commercial suppliers and were used directly without further purifications. All syntheses were carried out in a dry nitrogen atmosphere unless otherwise specified. Reactions were monitored by thin-layer chromatography (TLC, on Merck F 254 silica gel 60 aluminum sheets, spots were either visible under light or UV-light (254 mm) or stained with an oxidizing solution (KMnO 4 stain). The same TLC system was used to test purity, and all final products showed a single spot on TLC. Column chromatography was performed with silica gel. 1 H-NMR spectra were recorded on a Varian QE-300 spectrometer with deuterated chloroform (CDCl 3 ; δ = 7.24 ppm) or deuterated dimethyl sulfoxide (DMSO-d 6 ) containing TMS an internal standard. 13 C-NMR spectra were recorded on a Varian QE-300 spectrometer at 75 MHz. The purity of the inhibitors reported in this manuscript was determined either by 1) HPLC-UV using Agilent 1200 series HPLC series equipped with Phenomenex Luna2 C18 reverse phase column (C18, 4.6 mm x 150 mm, 5 µm) coupled with Agilent G1314 UV-vis detector (Detection at 230 nm) with isocratic flow at Methanol: Water (2:1 by volume) for 90 min; or by 2) H-NMR. The lowest obtained purity was reported. The inhibitor was dissolved in EtOH at 100 µM and 10 µL was injected on HPLC. Purity was based on the percent of total peak area at 230 nm using HPLC-UV. This purity estimate was compared with that from the H-NMR. The presence of anilines in the final product was estimated from H-NMR. The lowest obtained purity was reported. The purity was also further supported as described in the supplementary materials by LC/MS with monitoring of total ion current, TLC in several systems, a sharp melting point and occasional other technique. The elemental analysis was conducted by MIDWESTMICRO lab, LCC. The synthesis of tert-butyl 4-(3-(4-(trifluoromethyl)phenyl)ureido) piperidine-1-carboxylate, 1-(piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea, 1-(piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea and tert-butyl 4-(3-(4-(trifluoromethoxy)phenyl)ureido)piperidine-1-carboxylate have been reported elsewhere. 
Synthetic Method 1
Step 1 Corresponding isocyanate (1 equiv.) and 4-amino-1-Boc-piperidine (1.1 equiv.) was dissolved in CH 2 Cl 2 (50 mM, corresponding to isocyanate) and stirred at rt for 12h. The reaction was quenched by addition of water. The organic layer was isolated and the aqueous layer was extracted with EtOAc (EtOAc: Aqueous layer/ 1:1) for 4 times. The combined organic layer was dried over anhydrous magnesium sulfate and was concentrated under vacuo and was further purified by flash chromatography yielding corresponding Boc-protected urea.
Step 2 The Boc protected urea from the step 1 was dissolved in HCl solution (2M, MeOH) to make reaction mixture (186 mM, Boc protected urea). The resulting solution was refluxed for 2h. The solvent was removed under vacuo and the crude reaction product was adjusted to pH 12 with NaOH solution (6N). The precipitates were filtered and dried under high vacuum. The final product unprotected urea was served as a scaffold for the next step of synthesis.
Step 3 Unless specified, the unprotected urea (1 equiv.) from step 2, EDCI (1.5 equiv.), DMAP (1.5 equiv.) and corresponding carboxylic acid (1.5 equiv.) was dissolved in CH 2 Cl 2 (8.3 mM, unprotected urea) and was stirred overnight (12h) at rt. The reaction was quenched by addition of HCl solution (1M). The organic layer was collected and the aqueous layer was extracted with EtOAc (EtOAc: Aqueous layer/ 1:1) for 4 times. The combined organic layer was dried over anhydrous magnesium sulfate and was concentrated in vacuo and further purified by flash chromatography.
Synthetic Method 2
The corresponding isocyanate (1 equiv.) was added to a suspension of targeted piperidine (1.1 equiv.) in CH 2 Cl 2 (20 mM, corresponding isocyanate). The reaction was stirred overnight (12h) at rt. The reaction was quenched with the addition of HCl solution (2M). The organic layer was collected and the aqueous layer was further extracted with EtOAc (EtOAc: Aqueous layer/ 1:1) three times. The combined organic layer was washed with sat. NaCl solution. The organic layer was dried over anhydrous magnesium sulfate and was concentrated in vacuo. The product was purified by flash chromatography.
Synthetic Method 3
Corresponding amine (1 equiv.) and triethylamine (1.2 equiv.) was dissolved in CH 2 Cl 2 (54 mM corresponding to amine) and stirred at -78 ˚C. Triphosgene (0.37 equiv.) dissolved in CH 2 Cl 2 (20 mM, corresponding triphosgene) was added dropwise at -78 ˚C. The reaction was then warm to rt and was stirred for 30 min. The reaction was cooled to 0 ˚C. Corresponding piperidine (1.1 equiv.) dissolved in CH 2 Cl 2 (54 mM, corresponding piperidine) was added slowly and the reaction was further stirred at rt for 12 h. The reaction was quenched with the addition of HCl solution (2M). The organic layer was collected and the aqueous layer was further extracted with EtOAc (EtOAc: Aqueous layer/ 1:1) for three times. The combined organic layer was washed with sat. NaCl solution. The organic layer was dried over anhydrous magnesium sulfate and was concentrated in vacuo. The product was purified by flash chromatography.
Synthetic Method 4
The first two steps are the same as Synthetic Method 1, step 1 and step 2 unless specified.
Step 3 The unprotected urea (1 equiv.) and triethylamine (1.2 equiv.) was dissolved in CH 2 Cl 2 (8.3 mM, corresponding unprotected urea) and Corresponding sulfonyl chloride was added dropwise at 0 ˚C and the reaction was stirred overnight (12h) at rt. The reaction was quenched by addition of HCl solution (1M). The organic layer was collected and the aqueous layer was extracted with EtOAc (EtOAc: Aqueous layer/ 1:1) for 4 times. The combined organic layer was dried over anhydrous magnesium sulfate and was concentrated in vacuo and further purified by flash chromatography.
Synthesis of tert-butyl 4-(3-(4-(trifluoromethyl)phenyl)ureido)piperidine-1-carboxylate (A)
A 4-(Trifluoromethyl)phenyl isocyanate (1.068 g, 5.71 mmol) and 4-amino-1-Boc-piperidine (1.0 g, 5 mmol) was dissolved in CH 2 Cl 2 (100 mL) and stirred for 12h at rt. The reaction was quenched by addition of water (50 mL). The organic layer was isolated and the aqueous layer was extracted with EtOAc (50 mL) for 4 times. The combined organic layer was concentrated under vacuo and was further purified by flash chromatography (EtOAc:Hex/ 1:1) yielding final product (1) 
Synthesis of 1-(piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (B)
tert-butyl 4-(3-(4-(trifluoromethyl)phenyl)ureido)piperidine-1-carboxylate (1.6 g, 4.13 mmol) was dissolved in HCl solution (2M, MeOH, 100 mL). The resulting solution was refluxed for 2h. The solvent was removed under vacuo and the crude reaction product was taken to pH 12 with NaOH solution (6N). The final precipitates (0.9 g, 3.13 mmol, 78%) were filtered and dried under high vacuum. The final product (B) was served as a scaffold for the synthesis of the following urea inhibitors. 1 
Synthesis of tert-butyl 4-(3-(4-(trifluoromethoxy)phenyl)ureido)piperidine-1-carboxylate(C)
C 4-(Trifluoromethoxy)phenyl isocyanate (4 g, 19.7 mmol) and 4-amino-1-Boc-piperidine (4.3 g, 21.7 mmol) was dissolved in CH 2 Cl 2 (100 mL) and stirred for 12h. The reaction was quenched by addition of water (50 mL). The organic layer was isolated and the aqueous layer was extracted with EtOAc (50 mL) for 4 times. The combined organic layer was concentrated under vacuo and was further purified by flash chromatography (EtOAc:Hex/ 1:1) yielding final product (C) (7.5 g, 18.6 mmol, 94% 
Synthesis of 1-(piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (D)
tert-Butyl 4-(3-(4-(trifluoromethoxy)phenyl)ureido)piperidine-1-carboxylate (7.5 g, 18.6 mmol) was dissolved in HCl solution (2M, MeOH, 100 mL). The resulting solution was refluxed for 2h. The solvent was removed under vacuo and the crude reaction product was washed by dichloromethane twice (100 mL) and was adjusted to pH 12 by NaOH solution (6N). The final precipitates (5.6 g, 18.5 mmol, 99%) were filtered and dried under high vacuum. The final product (D) was served as a scaffold for the synthesis of the following urea inhibitors. 
Synthesis of 1-(1-acetylpiperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (1)
F 3 C N H N H NH O F 3 C N H N H N O O Acetic anhydride, DMAP CH 2 Cl 2 , 12h
B
Piperidine B (50 mg, 168 µmol) was dissolved in CH 2 Cl 2 (8.3 mM corresponding to unprotected urea).Acetic anhydride (25.4 mg, 251.7 µmol) was added dropwisely to the reaction mixture. The reaction mixture was stirred for 12h at rt. The reaction was quenched by addition of HCl (1M). The organic layer was collected and the aqueous layer was further extracted by EtOAc for 4 times. The combined organic layer was concentrated under vacuo. The product was purified by flash chromatography (EtOAc: Hexane/ 4:1). The product 1 was further purified by crystallization (MeOH with water). Yield: 47 mg, 85%. Purity (HPLC-UV): ≥99%. 
Synthesis of 1-(1-butyrylpiperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (3)
F 3 C N H N H NH O F 3 C N H N H N O O butanoic acid, DMAP, EDCI, CH 2 Cl 2 , 12h
B
The synthesis was carried out according to synthetic pathway 1, step 3. Piperidine B (50 mg, 168 µmol) was reacted with butanoic acid (22 mg, 251.7 µmol). The product was purified by flash chromatography with (EtOAc: Hexane/ 3:2). The product 3 was further purified by crystallization (MeOH with water).
Yield: 54.5mg, 91%. Purity (HPLC-UV): ≥99%. 
Synthesis of 1-(1-isobutyrylpiperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (4)
F 3 C N H N H NH O F 3 C N H N H N O O (CH 3 ) 2 CHCO 2 H, DMAP, EDCI, CH 2 Cl 2 , 12h
B
The synthesis was carried out according to synthetic pathway 1, step 3. Piperidine B (50 mg, 168 µmol) was reacted with 2-methylpropanoic acid (22 mg, 251.7 µmol). The product was purified by flash chromatography (EtOAc: Hexane/ 7:3). The product 4 was further purified by crystallization (MeOH with water).
Yield: 50.9 mg, 85%. Purity (HPLC-UV): ≥99%. 
Synthesis of 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (5)
The synthesis was carried out according to synthetic pathway 1, step 3. Piperidine B (50 mg, 168 µmol) was reacted with cyclopropanoic acid (22 mg, 252 µmol). The product was purified by flash chromatography (EtOAc: Hexane/ 1:1). The product 5 was further purified by crystallization (MeOH with water).
Yield: 48.3 mg, 81%. Purity (HPLC-UV): ≥99%. 
Synthesis of 1-(1-(2-methylbutyryl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (6)
The synthesis was carried out according to synthetic pathway 1, step 3. Piperidine B (50 mg, 168 µmol) was reacted with 2-methylbutyric acid (26 mg, 252 µmol). The product was purified by flash chromatography (EtOAc: Hexane/ 7:3). The product 6 was further purified by crystallization (MeOH with water).
Yield: 45 mg, 72%. Purity (HPLC-UV): ≥99%. 
Synthesis of (S)-1-(1-(2-methylbutanoyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (7)
The synthesis was carried out according to synthetic pathway 1, step 3. Piperidine B (50 mg, 168 µmol) was reacted with 2-methylbutyric acid (26 mg, 252 µmol). The product was purified by flash chromatography (EtOAc: Hexane/ 1:1). The product 7 was further purified by crystallization (MeOH with water).
Yield: 58 mg, 93%. Purity (HPLC-UV): ≥99%. 
Synthesis of 1-(1-(3-methylbutanoyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (8)
The synthesis was carried out according to synthetic pathway 1, step 3. Piperidine B (50 mg, 168 µmol) was reacted with isovaleric acid (26 mg, 252 µmol). The product was purified by flash chromatography (EtOAc: Hexane/ 1:1) yielding final product 8.
Yield: 50 mg, 80%. Purity (NMR): ≥95%.
Synthesis of 1-(1-(3,3,3-trifluoropropionyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (9)
The synthesis was carried out according to synthetic pathway 1, step 3. Piperidine B (50 mg, 168 µmol) was reacted with 3,3,3-trifluoropropionic acid (32 mg, 251 µmol). The product was purified by flash chromatography with (EtOAc: Hexane/ 7:3). The product 9 was further purified by crystallization (MeOH with water).
Yield: 51 mg, 76%. Purity (HPLC-UV): ≥99%. 
Synthesis of 1-(1-(4,4,4-trifluorobutanoyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (10)
Synthesis of 1-(4-aminopiperidin-1-yl)-2-methylbutan-1-one (E)
N
Synthesis of 1-(4-isopropylphenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (11)
The synthesis was carried out according to synthetic pathway 2. Piperidine E (40 mg, 217 µmol) was reacted with 4-isopropylphenyl isocyanate (38.5 mg, 239 µmol). The product 11 was purified by flash chromatography (EtOAc: Hexane/ 9:1).
Yield: 70 mg, 93%. Purity (HPLC-UV): ≥99%. (12) O O
Synthesis of 1-(4-tert-butylphenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea
E
The synthesis was carried out according to synthetic pathway 2. Piperidine E (40 mg, 217 µmol) was reacted with 4-tert-butylphenyl isocyanate (42 mg, 239 µmol). The product 12 was purified by flash chromatography (EtOAc: Hexane/ 9:1).
Yield: 65.5 mg, 84%. Purity (HPLC-UV): ≥99%. The synthesis followed the publish procedure. 8 Aniline (1g, 10.8 mmol), sodium dithionite (1.1g, 13 mmol), sodium hydrogen sulfate (1.1g, 13 mmol) and tetrabutylammonium hydrogen sulfate (0.4g, 1.2 mmol) were added successively to a mixture of water (20 mL) and methyl t-butyl ether (20 mL). heptafluoroisopropyl iodide (3.8g, 13 mmol) was added into reaction mixture and the mixture was stirred at rt for 12h. The organic layer was separated and the aqueous layer was further extracted with EtOAc for 2 times. The combined organic layer was dried under anhydrous Mg 2 SO 4 and concentrated under vacuo. The product (1.5g, 5.74 mmol, 53% yield) was further purified by flash chromatography (EtOAc:Hex/ 1:1). 1 
Synthesis of 1-(1-(2-methylbutanoyl)piperidin-4-yl)-3-(4-(perfluoropropan-2-yl)phenyl)urea (13)
NH
13
The synthesis was carried out according to synthetic pathway 3. Piperidine E (50 mg, 271.7 µmol) was reacted with 4-(perfluoropropan-2-yl)aniline (78 mg, 299 µmol). The product 13 was purified by flash chromatography (EtOAc: Hexane/ 8:2). The product 13 was further purified by crystallization (MeOH with water).
Yield: 114 mg, 89%. Purity (HPLC-UV): ≥99%. The synthesis was carried out according to synthetic pathway 2. Piperidine E (40 mg, 217 µmol) was reacted with 4-(trifluoromethoxy)phenyl isocyanate (48.5 mg, 239 µmol). The product 14 was purified by flash chromatography (EtOAc: Hexane/ 9:1). The product 14 was further purified by crystallization (MeOH with water).
Synthesis of 1-(1-(2-methylbutanoyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (14)
Yield: 75 mg, 89%. Purity (HPLC-UV): ≥99%. (15) (16) The synthesis was carried out according to synthetic pathway 3. Piperidine E (50 mg, 271.7 µmol) was reacted with trans-4-ethylcyclohexanamine (38 mg, 299 µmol). The product 17 was eluted by flash chromatography with EtOAc. The product 17 was further purified by crystallization (EtOAc in Hexane).
Synthesis of 1-cyclohexyl-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea
Synthesis of 1-cycloheptyl-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea
Synthesis of 1-(trans-4-ethylcyclohexyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (17)
Yield: 57 mg, 62%. Purity (NMR): ≥95%. The synthesis was carried out according to synthetic pathway 1, step 3. Piperidine D (50 mg, 168 µmol) was reacted with with (S)-2-methylbutanoic acid (26 mg, 252 µmol). The product 21 was purified by flash chromatography (EtOAc: Hexane/ 9:1). The product 21 was further purified by crystallization (MeOH with water).
Synthesis of 1-(1-isobutyrylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (19)
F
Synthesis of (S)-1-(1-(2-methylbutanoyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (21)
Yield: 54 mg, 83%. Purity (HPLC-UV): ≥99%. by EtOAc three times. The combined organic layer was dried over anhydrous MgSO 4 and concentrated under vacuo. The product 22 was purified by flash chromatography (EtOAc: Hexane/ 8:2).
Synthesis of (S)-N-(1-(2-methylbutanoyl)piperidin-4-yl)-2-(4-(trifluoromethoxy)phenyl)acetamide (22)
Yield: 114 mg, 65 %. Purity (NMR): ≥95%. 
Synthesis of (S)-2-(1-(2-methylbutanoyl)piperidin-4-yl)-N-(4-(trifluoromethoxy)phenyl)acetamide (23)
Synthesis of 1-(4-(perfluoropropan-2-yl)phenyl)-3-(1-(3,3,3-trifluoropropanoyl)piperidin-4-yl)urea (24)
24
F
The synthesis was carried out according to synthetic pathway 3. Piperidine F (60 mg, 285 µmol) was reacted with 4-(perfluoropropan-2-yl)aniline (82 mg, 314 µmol). The product 24 was eluted by flash chromatography with EtOAc. The product 24 was further purified by crystallization (EtOAc in Hexane).
Yield: 76.5 54%. Purity (HPLC-UV): ≥99%. The synthesis was carried out according to synthetic pathway 4. Piperidine B (50 mg, 168 µmol) was reacted with methanesulfonyl chloride (23 mg, 202 µmol). The synthesis was carried out according to synthetic pathway 4. Piperidine B (50 mg, 168 µmol) was reacted with propanesulfonyl chloride (28 mg, 202 µmol). The product 27 was eluted by flash chromatography with EtOAc:Hex (6:4). The product 27 was further purified by crystallization (EtOAc in Hexane). Yield: 41.5 mg, 63%. Purity (HPLC-UV): ≥99%. The synthesis was carried out according to synthetic pathway 4. Piperidine B (50 mg, 168 µmol) was reacted with cyclopropylsulfonyl chloride (28 mg, 202 µmol). The product 28 was eluted by flash chromatography with EtOAc:Hex (6:4). The product 28 was further purified by crystallization (EtOAc in Hexane). Yield: 45 mg, 68%. Purity (HPLC-UV): ≥99%. The synthesis was carried out according to synthetic pathway 4. Piperidine D (50 mg, 165 µmol) was reacted with butanesulfonyl chloride (31 mg, 198 µmol). The product 32 was eluted by flash chromatography with EtOAc:Hex (6:4). The product 32 was further purified by crystallization (EtOAc in Hexane 
Synthesis of 1-(1-(methylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (25)
Synthesis of 1-(1-(ethylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (26)
Synthesis of 1-(1-(propylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (27)
Synthesis of 1-(1-(cyclopropylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (28)
1H NMR (d6-
DMSO, 300 Mhz): ∂ 8.78 (s, 1H), 7.57 (s, 4H), 6.38 (d, J = 7.5 Hz, 1H), 4.19 (d, J = Hz, 1H), 3.52 (d, J = 12.3 Hz, 2H), 2.99 (t, J = 11.4 Hz, 2H), 2.58 (m, 1H), 1.91 (d, J = 12.6 Hz, 2H), 1.46 (m, 2H), 0.
Synthesis of 1-(1-(isopropylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (29)
Synthesis of 1-(1-(2,2,2-trifluoroethylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (30)
Synthesis of 1-(1-(butylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (31)
(calculated for [H + ]: C 17 H 25 F 3 N 3 O 3 S): 408.1563; found (ESI(+), [M-H + ]): 408.1541 Melting point (˚C): 230.4-231.1 (230.8)
Synthesis of 1-(1-(butylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea (32)
LogP Determination
The experimental logP were determined by two published methods. 9, 10 The results of these methods were compared to each other and then they were compared to logP calculated by ChemOffice algorithm and referred as clogP.
Shake-flask method
The inhibitor (10 mM, 20 uL of EtOH) was added to a mixture of water (saturated with octanol, 1 mL) and octanol (saturated with water, 1mL). The mixture was shaken (220 rpm) at rt for overnight in a sealed vial (4 mL). The sample (100 µL) from each layer was collected and diluted in a series of dilution (x10, x100, x1000) in MeOH and kept at -20 ˚C before it was analyzed by LC/MS-MS.
HPLC method
The logP was analyzed using an Agilent HPLC 1200 series equipped with G1314 UV-vis detector and Phenomenex Luna reverse phase column (C18, 4.6 mm x 150 mm, 5 µm particle size). The Inhibitors (100 µM, 10 µL) were injected and were run at isocratic gradient (MeOH:H 2 O/ 2:1 (v:v)) for 90 min with monitoring at 230 nm. A calibration curve was generated using several compounds with LogP obtained from shake flask method and the retention time obtained from HPLC method. (Figure S3 , R 2 = 0.98). LogP of the compounds were calculated from the calibration curve ( Figure S3 ) based on the retention time obtained.
Solubility determination Preparation of solubility sample
Each inhibitor (1mg) was added into the PB (0.1 M Sodium Phosphate, pH 7.4, 300 µL) to create a suspension. The suspension was then incubated and was shaken (220 rpm) at 30 ˚C for 24h. The suspension was cooled down to rt for 1h. The suspensions were centrifuged (10,000 rpm, 10 min, rt) using Centrifuge 5415D (Eppendorf, Hauppauge, NY). The supernatant was transferred to new 1.5 mL eppendorf tube and was further diluted 10 times by methanol. The solution was kept on ice for 15 min to precipitate all the salt. The solution was centrifuged (10,000 rpm, 10 min, 4 ˚C) by Accuspin TM MicroR (thermo Fisher, Freemont, CA) and the supernatant was transferred to vial and was kept at -20˚C before LC/MS-MS analysis.
Biochemistry
Enzyme preparation
Expression and purification of recombinant sEH followed the published procedure. 11 Briefly, sEH from human and rat were expressed in high yield in a baclovirous expression system. The sEH in the supernatant from insect cell culture was purified by affinity chromatography to yield high specific activity and apparent homogeneity on SDS-PAGE. 7 The enzyme was frozen by liquid nitrogen in small aliquots and thawed once at 0 ˚C immediately before use. IC 50 determination for human sEH Inhibitors IC 50 s of hsEH inhibitors were determined by fluorescent according to published procedures. [12] [13] [14] [15] [16] , the concentration of the inhibitor that blocks 50% of the enzyme activity, was determined based on regression of at least five datum points with a minimum of two points in the linear region of the curve on either side of the IC 50 .
FRET-Displacement assay procedure
The FRET assay was carried out as described previously. 7 In order to prevent leaching of fluorescence impurities from the plastic tube and non-specific binding to sEH inhibitors, the inhibitor stock solution (10 mM, DMSO) was stored in glass vials. In addition, sEH was diluted to desired concentration (20 nM) with sodium phosphate buffer (PB) (100 mM sodium phosphate, pH 7.4, 0.01% gelatin) to avoid loss of protein from nonspecific binding to the cuvette surface. All buffer used in this assay was filtered using sterilized filtration unit (Millipore® Durapore PVDF Membrane, pore size: 0.22 um)
Measurement in Quartz cuvette
The sEH (10 nM, 3 mL, 100 mM sodium phosphate, pH 7.4, 0.01% gelatin) was stirred and pre-incubated with reporting ligand-1-((3s,5s,7s)-adamantan-1-yl)-3-(1-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl)piperidin-4-yl)urea (ACPU) (1 equivalent, 20 nM, 100 mM sodium phosphate, pH 7.4) at 30 ˚C for 1h in a quartz cuvette. The fluorescence (455 nm, emission slit width = 12 nm, excited at 280 nm, excitation slit width = 1.0 nm) was measured. The enzyme-ligand complex was titrated with different sEH inhibitors at varying concentration until no more fluorescence quenching was observed. The relative fluorescence intensity was plotted against the concentration of inhibitor.
Measurement in 96-well plates
All the measurement for FRET-based displacement assay in 96-well plate format was done in TECAN Infinite ® M1000 Pro.
Pre-treatment of 96-well plate:
As mentioned, in order to prevent non-specific binding of sEH or inhibitor on the 96-well plate, the 96 well plates were pre-incubated with PB with 0.1% gelatin overnight at rt. The gelatin coats the plate and prevents non-specific binding of sEH and sEH inhibitors to the plate. The buffer was discarded and the plate was dried before use.
Assay procedure:
The sEH stock was diluted to the desired concentration (20 nM) by PB (100 mM sodium phosphate, 0.1 % gelatin, pH 7.4). ACPU (one equivalent to sEH, 10 mM, Ethanol) was added to the sEH solution and was incubated for 2h at rt. The sEH-ACPU mixture (20 nM, 100 mM sodium phosphate, 0.1 % gelatin, pH 7.4, 150 uL) was added to each well. The baseline fluorescence (F 0 ) (λexcitation at 280 nm, λemission at 450 nm) of the samples was measured after the zposition and gain were optimized automatically by the fluorometers. The z and gain value was noted and were used for the later fluorescent measurement. Because DMSO has been known to quench fluorescence. 1% DMSO in PB was served as a control (F DMSO ). The desired concentration of inhibitors which is the concentration that 100% of sEH was bound to inhibitor, was added at the first well and was further diluted by 2-fold across the rest of the wells. Based on our study, 12 datum points which correspond to 12 different concentrations of the inhibitor, generally sufficient data to calculate an accurate K i for the inhibitors. The samples were incubated at 30 ˚C for 1.5h. Then, the fluorescence (λexcitation at 280 nm, λemission at 450 nm) of the samples was measured using the z-position and gain values that previously obtained. The obtained fluorescence signals were transformed as below and were used to calculated the K i of the inhibitors according to "Curve fitting" section below.
Initiated fluorescence = F DMSO (well X) / F 0 (well X) Saturated fluorescence = F at the saturated concentration (well X) / F 0 (at well X) Observed fluorescence = F (well X) / F 0 (well X)
Curve fitting
The curve fitting for K i determination was reported before. 7 The data manipulation and K i calculation were based on the original paper by Wang et al. with modifications suggested by Roehrl et al. 17, 18 The data were fitted in to cubic equation (Eq. 2) using SigmaPlot (Systat Software, San Jose, CA). The displacement assay is based on a three-state equilibrium binding model. This is modeled as described below (Eq. The k off measurement was run as described before. 7 The sEH (8 µM) was pre-incubated with the selected inhibitor (8.8 µM, 100 mM PB buffer, pH 7.4) for 1.5 h at rt. The sEH-inhibitor complex was then diluted 40 times with ACPU (20 µM, 100 mM Sodium phosphate buffer, pH 7.4). The fluorescence (λexcitation at 280 nm, λemission at 450 nm) was monitored immediately for every 30s up to 5100s. The fluorescence (λemission at 450 nm) data was plotted against time (s). The resulting curve was fitted to single exponential growth and the relative k off was obtained.
Protein Crystallization
Crystals of the enzyme were obtained using the hanging drop vapor-diffusion method by mixing equal volumes of protein (8-12 mg/mL concentration in 100 mM sodium phosphate pH 7.4, 3 mM DTT ) and the reservoir solution (30% PEG 3350, 0-10 % sucrose) at 4º C. The crystals grew in approximately one week and belonged to the hexagonal space group P6 5 22 . Complexes of sEH with inhibitors 1770 or 4 have been obtained by soaking sEH crystals grown as described above in modified mother liquor (35 % PEG 3350, 50 mM sodium phosphate pH 7.4) supplemented with 1 mM solution of inhibitor for 1-7 days Data Collection Prior to the data collection, a suitable crystal was dipped for 30 seconds in a modified mother liquor solution (35% PEG 3350) with the addition of 10% glycerol as a cryoprotectant. Diffraction data were collected at 100 K at the XP station at the Center for Advance Microstructures and Devices at Louisiana State University with a MAR charge-coupled device camera (structure UC1770) or the NE-CAT beamline 24-ID-C at the Advance Photon Source equipped with the Pilatus 6M detector (structure 4). The images were processed and scaled using Biology Pharmacokinetic study of inhibitors using oral dosing in rodent PK protocols for pharmacokinetic study with mouse All the animal experiments were performed according to the protocols approved by the Animal Use and Care Committee of University of California-Davis. Male Swiss Webster mice (8-week old, 24-30 g) purchased from Charles River Laboratories were used for PK studies. Inhibitors for oral administration were dissolved in oleic acid-rich triglyceride containing 20% PEG400 (v/v) to give a clear solution. Blood (10 µL) was collected from the tail vein using a pipette tip rinsed with 7.5% EDTA(K 3 ) at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 h after administration of the inhibitor in a cassette of three to five compounds (Table S1 ) (0.3 mg/kg per compounds, 100-110 uL). Each group contained 3-4 animals. Each blood sample was immediately transferred to a tube containing 50 µL of water containing 0.1% EDTA. After being mixed strongly on a Vortex for 1 min, all samples were stored at -80 ºC until analysis. The blood samples were prepared for the measurement of sEH inhibitors according to the previously reported method by Liu et al. 
PK protocols for pharmacokinetic study with rat
All the animal experiments were performed according to the protocols approved by the Animal Use and Care Committee of University of California-Davis. Male Sprague-Dawley rats (n=4, 8 week old, 250-300 g) were used for pharmacokinetic study for sEH inhibitors. A cassette of four inhibitors (inhibitor 4, 7, 19 and 21, 0.3 mg/kg per inhibitors, 0.9 to 1.2 mL) was given by oral administration. Inhibitor was dissolved in oleic oil containing 5% polyethylene glycol 400 to form a clear solution. Blood (10 µL) was collected from the tail vein by using a pipette tip rinsed with 7.5% EDTA(K 3 ) at 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hour after oral dosing with the inhibitor. Each blood sample was immediately transferred to a tube containing 50 µL of water and mixed by Vortex for 1 min, all samples were stored at −80°C until analysis. The blood samples were prepared for the measurement of sEH inhibitors according to the previously reported method by Liu et al.
22
Analysis of sEH inhibitors in solubility, LogP and blood samples (Mass spec tables)
The inhibitors' concentrations in the samples were determined according to the previously reported method by Liu et al. 22 The tables below described the optimized conditions for monitoring parent sEH inhibitors by multiple reaction-monitoring mode (MRM) either on the Quattro Premier triple-quadrupole mass spectrometer (Waters, Milford, MA) or on the 4000 Q-TRAP triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) 
PK analysis
The PK parameters of individual mice were calculated by fitting the time course curve of blood concentration data to a non-compartmental analysis with the WinNonlin software (Pharsight, Mountain View, CA). Parameters estimated include time of maximum concentration (T max ), maximum concentration (C max ), half life (t1/2), and area under the concentration-time curve to terminal time (AUC t ). AUC was calculated by the linear/log trapezoidal rule. Diabetic neuropathic pain model A diabetic neuropathic pain modeled was generated using streptozocin which targets and kills the pancreatic beta islet cells rendering the animals with type I diabetes. The rats were acclimated for one hour and tested for baseline thresholds before inducing diabetes. The baseline mechanical withdrawal thresholds were established using the von Frey mechanical nociceptive test with an electronic anesthesiometer (IITC, Woodland Hills, CA). Subsequently, streptozocin (55 mg/kg) in saline was injected via tail vein per previously reported methods 23 . After five days the allodynia of diabetic rats was confirmed with the von Frey nociceptive assay. Rats were placed in clear acrylic chambers on a steel mesh floor. The hind paw of the rat was probed through the mesh with a rigid tip probe connected to the electronic readout pressure meter set to the maximum hold setting. The withdrawal thresholds per rat were measured 3-5 times at 1 minute intervals for each time point. The baseline diabetic allodynia was quantified again at the beginning of all test days. The rats were then administered vehicle or sEH inhibitor via oral gavage and tested at 30min, 1, 2, 3, 4, 5, 6 and 8 h for mechanical withdrawal thresholds. The reported scores are the grams of force required to elicit a hind paw withdrawal averaged with standard error of the mean (S.E.M.) per a group of rats (n=5). The baseline diabetic neuropathic scores are normalized to 100 percent to reflect the response to treatments which are reported as % of post diabetic neuropathic baseline.
